Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCINTERVENTIONS.113.001033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Percutaneous bicaval valve implantation for severe tricuspid regurgitation due to carcinoid syndrome.
Singapore Med J
October 2024
Parkway Cancer Centre, Mount Elizabeth Hospital, Singapore.
Tricuspid Regurgitation in a Patient with Heart Transplant: Percutaneous Management.
Rev Med Chil
March 2024
Department of Cardiology, Instituto Nacional del Tórax, Santiago, Chile.
Tricuspid regurgitation (TR) is the most frequent valvular complication after heart transplantation with different clinical sequelae. In its most severe form, it can cause right heart failure with a poor long-term prognosis. Its management is complex, both medical, surgical, and percutaneous.
View Article and Find Full Text PDFImplantable cardioverter-defibrillator lead failure and revision following transcutaneous bicaval valve (TricValve®) implantation.
J Cardiovasc Electrophysiol
May 2024
Department of Cardiology, Wellington Regional Hospital, Te Whatu Ora Capital and Coast, Newtown, Wellington, New Zealand.
Introduction: Tricuspid regurgitation is associated with significant morbidity and mortality, and occurs at a higher rate in patients with cardiovascular implantable electronic devices. Percutaneous strategies for managing tricuspid regurgitation are evolving, including the development of bicaval valve implantation which has been successfully used in patients with pacing leads.
Methods And Results: We present the first documented case of lead failure following TricValve® implantation, a dedicated self-expanding system for bicaval valve implantation, and the first successful lead revision procedure in this setting.
Heart Transplantation in a Patient With a Heterotopic Percutaneous Tricuspid Valve Prosthesis: A Case Report.
Transplant Proc
December 2023
Cardiac Surgery Department, Heart Area, Virgen del Rocío University Hospital, Seville, Spain.
The bicaval transcatheter prosthesis (TricValve) allows the treatment of cava reflux in patients with severe tricuspid regurgitation and high surgical risk. It consists of the implantation of 2 self-expanding valves in both vena cava without directly approaching the native tricuspid valve. Heart transplantation in this setting may require some modifications compared with the conventional bicaval technique.
View Article and Find Full Text PDFHeterotopic caval valve-in-valve procedure for prosthetic migration: two case reports.
Eur Heart J Case Rep
August 2023
Cardiology Service, Central Lisbon Hospital and University Centre, Lisbon, Portugal.
Background: Heterotopic bicaval stenting or caval valve implantation (CAVI) either with non-dedicated balloon-expandable Sapien™ valves (Edwards Lifesciences) or with dedicated TricValve™ (Products + Features) has emerged as a safe and effective percutaneous treatment for high-risk patients with severe tricuspid regurgitation (TR). One technical difficulty of CAVI is the lack of native calcified structures to anchor the device, which may lead to paravalvular leak or migration.
Cases Summary: We describe two patients with severe TR and high surgical risk who underwent CAVI procedures, both of them complicated with device migration to the right atrium (one inferior vena cava device and one superior vena cava device).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!